Business
OPKO HEALTH, INC.: Through our pharmaceutical business, we manufacture and sell Rayaldee , a U.S.
Revenue decreased 14.9% to $606.9M, while Net income decreased 324.0% to ($225.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $606.9MWatch
- Profitability — Net income ($225.7M)Watch
- Cash generation — Free cash flow ($190.8M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 6 buys; 0 sells in 365 daysOK
- Capital — share repurchases were $47.0MNote
Where the revenue comes from
Fiscal 2025, as OPKO HEALTH, INC. reports it. History and quarterly detail are in the app.
- Service$370.3M
- Product$156.9M
- Transfer Of Intellectual Property And Other$79.7M
- Rayaldee$59.4M
- Royalty$31.9M
Leadership changes
From OPKO HEALTH, INC.'s own filings, the day they're filed.
- Subbarao V. Uppaluri · director · departureeff. 2026-03-18
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-07-27
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-18
- DEF 14A · Annual proxy (pay & governance)2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about OPKO HEALTH, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.